1147 GMT - Novartis's 2025 guidance lift for both sales and profits should be well-received among investors, Jefferies analysts say in a note. The Swiss drugmaker's higher revenue, a better gross margin and lower R&D spend drove its core operating income above consensus, the analysts say. "We believe we could see a continuing beat-and-raise story this year," they say. Shares rise 0.7% to 94.04 euros.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
Novartis shares rise 0.7% to 94.04 Swiss francs. "Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk," at 1147 GMT, misstated the currency.
(END) Dow Jones Newswires
April 29, 2025 07:54 ET (11:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。